Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge

Why It Matters

The moves underscore how AI‑driven R&D and aggressive M&A are reshaping pharma pipelines, while price competition in the lucrative GLP‑1 obesity space threatens growth projections for incumbents.

Key Takeaways

• Gilead to buy Tubulis for up to $5 billion, boosting ADC pipeline
• Lilly acquires Centessa for up to $7.8 billion, expanding sleep‑disorder portfolio
• Biogen purchases Apellis for up to $6.1 billion, strengthening rare‑disease immunology
• Wegovy competition forces Lilly to lower 2026 Foundayo sales forecast
• AI agents enable drug design from text prompts, accelerating discovery

Pulse Analysis

The rise of agentic artificial intelligence is reshaping how biotech companies discover medicines. Platforms that translate a simple text prompt into a viable molecular scaffold allow researchers to bypass weeks of manual design, cutting lead‑generation cycles dramatically. Extended‑reality guided experiments further accelerate validation, creating a feedback loop where AI proposes, tests, and refines candidates with minimal human intervention. Industry analysts see this as a catalyst for faster pipelines, lower R&D spend, and a democratization of early‑stage drug design that could level the playing field for smaller innovators.

Strategic M&A activity reflects the scramble to embed these capabilities and broaden therapeutic reach. Gilead’s agreement to acquire Tubulis for up to $5 billion bolsters its antibody‑drug conjugate (ADC) platform, positioning the company for a stronger oncology pipeline. Simultaneously, Eli Lilly’s $7.8 billion purchase of Centessa adds a late‑stage sleep‑disorder portfolio, while Biogen’s $6.1 billion deal for Apellis secures rare‑disease immunology assets. Together, the transactions illustrate a wave of billion‑dollar bets aimed at diversifying revenue streams and locking in next‑generation biologics.

The obesity market, however, remains a battleground for pricing and market share. Novo Nordisk’s once‑dominant Wegovy injection now faces competition from Lilly’s oral GLP‑1 candidate, Foundayo, which recently earned FDA approval. Intensified price pressure forced Lilly to temper its 2026 sales outlook, signaling that even breakthrough oral formulations must contend with entrenched brand loyalty and aggressive payer negotiations. Investors will watch how Lilly balances its oral product’s convenience advantage against Wegovy’s established efficacy record, while the broader GLP‑1 class continues to expand into new indications.